Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$82.57 USD

82.57
7,726,928

+0.05 (0.06%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $82.57 0.00 (0.00%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

MASI Stock Gains as US Court Raises Concern About Politan's Ethics

Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.

Stryker Stock Declines Despite Completion of care.ai Acquisition

SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.

Here's Why Boston Scientific (BSX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.

Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session.

Is Phibro Stock Worth Retaining in Your Portfolio Now?

PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.

Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS

MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.

QGEN Stock Likely to Gain From Innovation Amid Competition

To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.

DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout

With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.

Should You Continue to Retain MYGN Stock in Your Portfolio?

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

PEN Stock to Gain From CE Mark Approval for its CAVT Technologies

Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.

ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan

The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.

IINN Stock Gains on Second US Patent Approval for VORTX System

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.

KIDS Stock Gains From Its New Enabling Technologies Division Launch

OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.

PAHC Stock Gains From Innovation, Market Expansion Goal

Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.

CVS Stock Gains From Its Birth Control Prescribing Service Launch

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio

Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.

Factors Driving Veeva Stock More Than 20% in Three Months

Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.

Owens & Minor Stock to Gain From New Collaboration With Google Cloud

OMI announces partnership with Google Cloud to enhance existing QSight capabilities.